CCL2 -2518 A/G Single Nucleotide Polymorphism As a Risk Factor for Breast Cancer

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2010 Jun 22

PMID 20563852

Citations 9

Authors

Lukasz Kruszyna

Margarita Lianeri

Blazej Rubis

Hanna Knula

Maria Rybczynska

Sylwia Grodecka-Gazdecka

Pawel P Jagodzinski

Affiliations

Soon will be listed here.

Abstract

The contribution of the CCL2 -2518 A>G (rs 1024611) polymorphism in the occurrence and progression of various cancers has been found to be discordant. We studied the prevalence of the CCL2 -2518 A>G polymorphism in patients with breast cancer (n = 160) and controls (n = 323) in a sample of the Polish population. There were no significant differences in CCL2 -2518 A>G genotypes between patients with breast tumors and controls. Odds ratio (OR) for patients bearing the GG genotype was 1.481 (95% CI = 0.7711-2.845, P = 0.2358), and OR of the GG and AG genotypes was 0.7269 (95% CI = 0.4967-1.064, P = 0.1002). There was also no significant distinction in the prevalence of alleles between patients and healthy individuals. OR for the CCL2 -2518 G allele frequency was 0.8903 (95% CI = 0.6611-1.199, P = 0.4441). Analysis of the association between tumor size, lymph node metastases, histological grade, and distribution of genotypes and alleles for the CCL2 -2518 A>G polymorphism also did not show significant differences. Our results did not show association of the CCL2 -2518 A>G polymorphism with breast cancer occurrence and clinical characteristics in a sample of the Polish cohort.

Citing Articles

The rs1024611 in the CCL2 gene and risk of gynecological cancer in Asians: a meta-analysis.

He S, Zhang X World J Surg Oncol. 2018; 16(1):34.

PMID: 29458367 PMC: 5819160. DOI: 10.1186/s12957-018-1335-4.

CCL2 Serum Levels and Adiposity Are Associated with the Polymorphic Phenotypes -2518A on CCL2 and 64ILE on CCR2 in a Mexican Population with Insulin Resistance.

Guzman-Ornelas M, Petri M, Vazquez-Del Mercado M, Chavarria-Avila E, Corona-Meraz F, Ruiz-Quezada S J Diabetes Res. 2016; 2016:5675739.

PMID: 26839895 PMC: 4709622. DOI: 10.1155/2016/5675739.

Impact of chemokines CCR5∆32, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population.

Singh V, Jaiswal P, Kapoor R, Kapoor R, Mittal R Tumour Biol. 2014; 35(5):4765-72.

PMID: 24430363 DOI: 10.1007/s13277-014-1624-7.

Impact of CCL2 and Its Receptor CCR2 Gene Polymorphism in North Indian Population: A Comparative Study in Different Ethnic Groups Worldwide.

Singh V, Srivastava N, Srivastava P, Mittal R Indian J Clin Biochem. 2014; 28(3):259-64.

PMID: 24426221 PMC: 3689333. DOI: 10.1007/s12291-012-0265-0.

Association between MCP-1 -2518A/G polymorphism and cancer risk: evidence from 19 case-control studies.

Da L, Zhang Y, Zhang S, Qian Y, Zhang Q, Jiang F PLoS One. 2013; 8(12):e82855.

PMID: 24367564 PMC: 3867394. DOI: 10.1371/journal.pone.0082855.

References

Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M . Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer. 2009; 125(6):1276-84. DOI: 10.1002/ijc.24378. View

Nahon P, Sutton A, Rufat P, Faisant C, Simon C, Barget N . Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study. Eur J Gastroenterol Hepatol. 2007; 19(5):425-31. DOI: 10.1097/MEG.0b013e3280120e2b. View

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

Mestdagt M, Polette M, Buttice G, Noel A, Ueda A, Foidart J . Transactivation of MCP-1/CCL2 by beta-catenin/TCF-4 in human breast cancer cells. Int J Cancer. 2005; 118(1):35-42. PMC: 2965755. DOI: 10.1002/ijc.21291. View

Nahon P, Sutton A, Rufat P, Simon C, Trinchet J, Gattegno L . Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol. 2008; 14(5):713-9. PMC: 2683997. DOI: 10.3748/wjg.14.713. View

Camp B, Dyhrman S, Memoli V, Mott L, Barth Jr R . In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann Surg Oncol. 1996; 3(2):176-84. DOI: 10.1007/BF02305798. View

Takahashi M, Miyazaki H, Furihata M, Sakai H, Konakahara T, Watanabe M . Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model. Clin Exp Metastasis. 2009; 26(7):817-28. DOI: 10.1007/s10585-009-9281-8. View

Huang C, Chern H, Chang K, Cheng C, Hsu S, Shen C . Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 1999; 59(19):4870-5. View

OSullivan C, Lewis C . Tumour-associated leucocytes: friends or foes in breast carcinoma. J Pathol. 1994; 172(3):229-35. DOI: 10.1002/path.1711720302. View

10.

Menard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N . Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res. 1997; 3(5):817-9. View

11.

Ghilardi G, Biondi M, La Torre A, Battaglioli L, Scorza R . Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G allele. Clin Chem. 2005; 51(2):452-5. DOI: 10.1373/clinchem.2004.041657. View

12.

Goede V, Brogelli L, Ziche M, Augustin H . Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer. 1999; 82(5):765-70. DOI: 10.1002/(sici)1097-0215(19990827)82:5<765::aid-ijc23>3.0.co;2-f. View

13.

Dapic V, Carvalho M, Monteiro A . Breast cancer susceptibility and the DNA damage response. Cancer Control. 2005; 12(2):127-36. DOI: 10.1177/107327480501200210. View

14.

Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, Jonjic N . Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract. 1998; 194(5):335-40. DOI: 10.1016/S0344-0338(98)80057-5. View

15.

Jass J . Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol. 1986; 39(6):585-9. PMC: 499954. DOI: 10.1136/jcp.39.6.585. View

16.

Vazquez-Lavista L, Lima G, Gabilondo F, Llorente L . Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology. 2009; 74(2):414-8. DOI: 10.1016/j.urology.2009.04.016. View

17.

Galvan A, Ioannidis J, Dragani T . Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet. 2010; 26(3):132-41. PMC: 2826571. DOI: 10.1016/j.tig.2009.12.008. View

18.

Carpi A, Nicolini A, Antonelli A, Ferrari P, Rossi G . Cytokines in the management of high risk or advanced breast cancer: an update and expectation. Curr Cancer Drug Targets. 2009; 9(8):888-903. DOI: 10.2174/156800909790192392. View

19.

Vargo-Gogola T, Rosen J . Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 2007; 7(9):659-72. DOI: 10.1038/nrc2193. View

20.

Attar R, Agachan B, Bulgurcuoglu Kuran S, Cacina C, Sozen S, Yurdum L . Association of CCL2 and CCR2 gene variants with endometrial cancer in Turkish women. In Vivo. 2010; 24(2):243-8. View